Status:
COMPLETED
Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
Lead Sponsor:
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Collaborating Sponsors:
CytoPharm, Inc.
Conditions:
Influenza A Virus Infection
Eligibility:
All Genders
20-65 years
Phase:
PHASE2
Brief Summary
This study aims to evaluate the safety and effect of interferon-alpha lozenges when used in combination with oseltamivir (Tamiflu) to treat influenza.
Eligibility Criteria
Inclusion
- fever \>=38C
- one or more respiratory symptoms (e.g. cough, rhinorrhea or sore throat) plus one or more constitutional symptoms (e.g. chills, headache, malaise and myalgias)of \< 48 hours' duration
- body weight \> 40 kg
- positive for influenza A (nasal swab rapid test)
Exclusion
- pregnancy/lactation
- history of depression or psychiatric disorders
- history of conditions that could complicate flu infection, such as chronic pulmonary, cardiac, renal, or metabolic disorders
- use of immunosuppressive therapy
- HIV infection
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01146535
Start Date
January 1 2011
End Date
December 1 2012
Last Update
August 21 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Medical Foundation, LinKou Branch
Guishan, Taoyuan County, Taiwan, 333
2
Kaohsiung Veterans General Hospital
Kaohsiung City, Zuoying District, Taiwan, 81362
3
Show-Chwan Memorial Hospital
Changhua, Taiwan, 800
4
Taiwan Municipal Hospital
Tainan, Taiwan, 701